NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Entera BIO Ltd. ENTX
6 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$42,000
▼ 76.8% vs FY2024
EPS · FY25
$-0.25
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-108.0%
Net margin · FY25
-27235.7%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 42,000.00
Revenue, FY2025 · full 6-year series below
Revenue
Net income
The company lost 27236 cents on every revenue dollar this year.
Per share
USD -0.25
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-108.0%
Return on equity, FY2025
ROE
Operating margin-27450.0%
Net margin-27235.7%
Return on assets-90.1%
Each USD of equity lost 108 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−35.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−32.1%
−35.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.05B
Shares outstanding, FY2025
Change, 5 years+119.3%
Change, 10 years—
The share count grew 119% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 16.0M
total assets, end of FY2025
Total assetsUSD 16.0M
EquityUSD 13.1M
CashUSD 7.1M
Current ratio6.94×
Equity funds 82% of total assets.
History
6 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
−0.0
0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.25
−0.25
−0.31
−0.45
−0.47
0.67
Dividend / sh $
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
ROE %
−108.0
−103.3
−80.3
−76.2
−81.0
−105.4
Shares out B
0.05
0.04
0.04
0.03
0.03
0.02
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
23 of 24
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 1 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed